Exhibit 99.1
Masimo Reports Second Quarter 2010 Financial Results
Total quarterly revenue exceeds $100 million for first time in company’s history
Q2 2010 Highlights (compared to Q2 2009):
| • | Total revenue rose 20% to $100.1 million |
| • | Product revenue rose 26% to $88.0 million |
| • | Masimo SET and Masimo Rainbow SET unit shipments rose 35% to 36,700 |
| • | Rainbow revenue rose 60% to $7.2 million |
| • | GAAP EPS of $0.24 included $0.01 in one-time expenses. Adjusted EPS of $0.25, compared to $0.22 in year-ago period |
Irvine, California, August 3, 2010 –Masimo Corporation (NASDAQ: MASI), today announced its financial results for the second quarter of 2010.
Masimo’s total revenue for the second quarter rose 19.8% to $100.1 million, compared to $83.6 million for the second quarter of 2009. Masimo’s second quarter product revenue rose 25.6% to $88.0 million, compared to $70.0 million for the second quarter of 2009. Revenue from Masimo Rainbow SET products rose 59.5% to $7.2 million in the second quarter, compared to $4.5 million for the second quarter of 2009.
Net income for the second quarter was $14.3 million, or $0.24 per diluted share, including $0.01 per diluted share in one-time marketing-related expenses that Masimo had previously planned and announced after receiving $30.1 million in proceeds from an antitrust lawsuit against Covidien in the first quarter of 2010. Excluding these one-time expenses, adjusted net income for the second quarter was $15.2 million, or $0.25 per diluted share, compared to net income of $13.1 million, or $0.22 per diluted share, in the second quarter of 2009.
During the second quarter, the company shipped 36,700 Masimo SET pulse oximetry and Masimo Rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 35.4% compared to 27,100 in the same period last year. Masimo estimates its worldwide installed base as of July 3, 2010 to be 789,000 units, up 16.9% from 675,000 as of July 4, 2009.
Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “Masimo’s second quarter results reveal momentum across virtually all parts of our business, demonstrating the underlying strength and value of our technology to clinicians and patients. Our core SET franchise grew by double digits again this quarter and revenue from Rainbow SET products achieved a new high, allowing Masimo to deliver our first-ever $100 million revenue quarter. Our second quarter performance reflects strong domestic and international customer demand from both our direct and OEM sales channels. The quarter was also highlighted by the launch of two new Masimo innovations: Rainbow Acoustic Monitoring for continuous and noninvasive respiration rate monitoring, and Pronto-7, a palm-sized device for noninvasive spot-check hemoglobin testing.”
As of July 3, 2010, cash, cash equivalents and short-term investments totaled $111.0 million, compared to $189.0 million as of January 2, 2010. The decline was due primarily to the March 31, 2010 dividend payment of $117.5 million, partially offset by the net proceeds from the antitrust lawsuit and operating cash flow in the first six months of 2010.
Conference Call
Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 679-9937 for international callers. The reservation code for both dial-in numbers is 88305128. A live webcast of the conference call will be available online from the investor relations page of the company’s corporate web site at www.masimo.com. After the live webcast, the call will be available on Masimo’s website through September 3, 2010. In addition, a telephonic replay of the call will be available through August 17, 2010. The replay dial-in numbers are (800) 642-1687 for domestic callers and +1 (706) 645-9291 for international callers. Please use reservation code 88305128.
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Rainbow Pulse
CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced Rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo’s Rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of “Improving Patient Outcomes and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com. Any information contained in, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way a part of, this release.
Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our financial condition, results of operations and business generally. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo Rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors’ assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any new or existing products and technologies of ours; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce the anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
# # #
| Investor Contact:Sheree Aronson | Media Contact:Dana Banks | |
| Vice President, Investor Relations, Masimo Corporation | Manager, Public Relations, Masimo Corporation | |
| (949) 297-7043 | (949) 297-7348 | |
| saronson@masimo.com | dbanks@masimo.com |
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.
MASIMO CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
| July 3, 2010 | January 2, 2010 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 110,971 | $ | 132,054 | ||||
Short-term investments | — | 56,989 | ||||||
Accounts receivable, net of allowance for doubtful accounts | 49,093 | 38,897 | ||||||
Royalties receivable | 11,500 | 11,500 | ||||||
Inventories | 37,110 | 31,559 | ||||||
Prepaid expenses | 4,158 | 5,447 | ||||||
Deferred tax assets | 11,589 | 11,585 | ||||||
Other current assets | 1,445 | 1,357 | ||||||
Total current assets | 225,866 | 289,388 | ||||||
Deferred cost of goods sold | 32,557 | 28,163 | ||||||
Property and equipment, net | 13,083 | 11,682 | ||||||
Deferred tax assets | 11,363 | 11,500 | ||||||
Intangible assets, net | 10,129 | 9,829 | ||||||
Other assets | 7,653 | 5,783 | ||||||
Total assets | $ | 300,651 | $ | 356,345 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 21,751 | $ | 16,716 | ||||
Accrued compensation | 15,833 | 17,793 | ||||||
Accrued liabilities | 9,541 | 9,754 | ||||||
Income taxes payable | 1,013 | 477 | ||||||
Deferred revenue | 15,585 | 14,641 | ||||||
Current portion of capital lease obligation | 58 | 60 | ||||||
Total current liabilities | 63,781 | 59,441 | ||||||
Deferred revenue | 2,029 | 270 | ||||||
Capital lease obligation, less current portion | 145 | 171 | ||||||
Other liabilities | 7,839 | 6,775 | ||||||
Total liabilities | 73,794 | 66,657 | ||||||
Stockholders’ equity | ||||||||
Common stock | 59 | 58 | ||||||
Treasury stock | (1,209 | ) | (1,209 | ) | ||||
Additional paid-in capital | 208,329 | 195,690 | ||||||
Accumulated other comprehensive income | 517 | 63 | ||||||
Retained earnings | 17,603 | 94,112 | ||||||
Total Masimo Corporation stockholders’ equity | 225,299 | 288,714 | ||||||
Noncontrolling interest | 1,558 | 974 | ||||||
Total stockholders’ equity | 226,857 | 289,688 | ||||||
Total liabilities and stockholders’ equity | $ | 300,651 | $ | 356,345 | ||||
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited, in thousands, except per share amounts)
| Three Months Ended | Six Months Ended | |||||||||||||||
| July 3, 2010 | July 4, 2009 | July 3, 2010 | July 4, 2009 | |||||||||||||
Revenue: | ||||||||||||||||
Product | $ | 87,958 | $ | 70,047 | $ | 173,824 | $ | 144,544 | ||||||||
Royalty | 12,122 | 13,522 | 25,021 | 24,517 | ||||||||||||
Total revenue | 100,080 | 83,569 | 198,845 | 169,061 | ||||||||||||
Cost of goods sold | 29,775 | 23,574 | 59,003 | 48,319 | ||||||||||||
Gross profit | 70,305 | 59,995 | 139,842 | 120,742 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 9,051 | 7,252 | 18,461 | 15,019 | ||||||||||||
Selling, general and administrative | 41,004 | 32,766 | 90,315 | 65,646 | ||||||||||||
Antitrust litigation expense (proceeds) | (760 | ) | 29 | (30,728 | ) | 43 | ||||||||||
Total operating expenses | 49,295 | 40,047 | 78,048 | 80,708 | ||||||||||||
Operating income | 21,010 | 19,948 | 61,794 | 40,034 | ||||||||||||
Non-operating income (expense) | 309 | 368 | (38 | ) | 81 | |||||||||||
Income before provision for income taxes | 21,319 | 20,316 | 61,756 | 40,115 | ||||||||||||
Provision for income taxes | 7,403 | 7,065 | 21,676 | 13,600 | ||||||||||||
Net income including noncontrolling interests | 13,916 | 13,251 | 40,080 | 26,515 | ||||||||||||
Net (income) loss attributable to the noncontrolling interests | 371 | (159 | ) | 917 | (402 | ) | ||||||||||
Net income attributable to Masimo Corporation | $ | 14,287 | $ | 13,092 | $ | 40,997 | $ | 26,113 | ||||||||
Net income per share attributable to Masimo Corporation stockholders: | ||||||||||||||||
Basic | $ | 0.24 | $ | 0.23 | $ | 0.70 | $ | 0.45 | ||||||||
Diluted | $ | 0.24 | $ | 0.22 | $ | 0.68 | $ | 0.43 | ||||||||
Weighted average shares used in per share calculations: | ||||||||||||||||
Basic | 58,798 | 57,552 | 58,532 | 57,480 | ||||||||||||
Diluted | 60,510 | 60,185 | 60,496 | 60,177 | ||||||||||||
Cash dividend declared per share | $ | — | $ | — | $ | 2.00 | $ | — | ||||||||
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)
| Six Months Ended | ||||||||
| July 3, 2010 | July 4, 2009 | |||||||
Cash flows from operating activities: | ||||||||
Net income including noncontrolling interests | $ | 40,080 | $ | 26,515 | ||||
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 3,151 | 3,063 | ||||||
Share-based compensation | 6,318 | 5,473 | ||||||
Loss on disposal of property and equipment | — | 5 | ||||||
Provision for doubtful accounts | 154 | 370 | ||||||
Provision for obsolete inventory | 359 | 527 | ||||||
Provision for warranty costs | 1,150 | 981 | ||||||
Provision for deferred income taxes | 133 | — | ||||||
Income tax benefit from exercise of stock options granted prior to January 1, 2006 | 1,631 | 820 | ||||||
Excess tax benefit from share-based payment arrangements | (537 | ) | (152 | ) | ||||
Changes in operating assets and liabilities: | ||||||||
Increase in accounts receivable | (10,338 | ) | (8,295 | ) | ||||
Decrease in royalties receivable | — | 269 | ||||||
Increase in inventories | (5,910 | ) | (2,994 | ) | ||||
Increase in deferred cost of goods sold | (4,499 | ) | (497 | ) | ||||
(Increase) decrease in prepaid expense | 1,243 | (2,148 | ) | |||||
Increase in other assets | (2,003 | ) | (250 | ) | ||||
Increase (decrease) in accounts payable | 5,084 | (1,869 | ) | |||||
Decrease in accrued compensation | (1,752 | ) | (2,000 | ) | ||||
Decrease in accrued liabilities | (1,291 | ) | (192 | ) | ||||
Increase (decrease) in income taxes payable | 1,073 | (10,403 | ) | |||||
Increase in deferred revenue | 2,703 | 1,493 | ||||||
Increase in other liabilities | 1,064 | 416 | ||||||
Net cash provided by operating activities | 37,813 | 11,132 | ||||||
Cash flows from investing activities: | ||||||||
Purchase of short-term investments | (75,986 | ) | — | |||||
Proceeds from sale and maturities of short-term investments | 132,975 | — | ||||||
Purchases of property and equipment | (3,930 | ) | (1,987 | ) | ||||
Increase in intangible assets | (911 | ) | (743 | ) | ||||
(Increase) decrease in restricted cash | 40 | (15 | ) | |||||
Net cash provided by (used in) investing activities | 52,188 | (2,745 | ) | |||||
Cash flows from financing activities: | ||||||||
Repayments on long-term debt | (28 | ) | (255 | ) | ||||
Proceeds from issuance of common stock | 5,662 | 1,415 | ||||||
Excess tax benefit from share-based payment arrangements | 537 | 152 | ||||||
Dividends paid | (117,506 | ) | — | |||||
Net cash provided by (used in) financing activities | (111,335 | ) | 1,312 | |||||
Effect of foreign currency exchange rates on cash | 251 | (43 | ) | |||||
Net increase (decrease) in cash and cash equivalents | (21,083 | ) | 9,656 | |||||
Cash and cash equivalents at beginning of period | 132,054 | 146,910 | ||||||
Cash and cash equivalents at end of period | $ | 110,971 | $ | 156,566 | ||||